ASCENTAGE PHARMA GROUP (ASX: 06855) has announced that significant clinical progress for its core products was presented at the 2026 European Hematology Association (EHA) Congress, featuring a total of 17 presentations including eight poster displays.

The data showcased the company's two flagship products: olverembatinib (marketed as Nirlix®; R&D code: HQP1351), China's first commercially available third-generation BCR-ABL inhibitor, and lisaftoclax (marketed as Lishento®; R&D code: APG-2575), China's first domestically developed, novel selective Bcl-2 inhibitor. These presentations comprehensively demonstrated the company's extensive pipeline and global innovation capabilities in the field of hematological malignancies.

The 2026 EHA Congress was held in Stockholm, Sweden, from June 11 to June 14, 2026. At this year's event, olverembatinib presented updated key evidence-based data across two therapeutic areas: chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

In the CML field, olverembatinib demonstrated durable and deep therapeutic efficacy in chronic phase (CML-CP) patients who are resistant and/or intolerant to first-line TKI therapy without the T315I mutation, showing strong potential as a second-line treatment. For CML-CP patients who have failed at least two prior TKI therapies, olverembatinib can be considered a standard treatment. Furthermore, clinical data for the product in multi-line TKI-resistant CML patients with high-risk genetic mutations were positive.

In the Ph+ ALL field, olverembatinib continued to show robust efficacy. Data from its global pivotal Phase III trial (POLARIS-1) further validated its excellent deep response rates and manageable safety profile. In specific patient subgroups, such as pediatric patients with relapsed/refractory Ph+ ALL, a chemotherapy-free combination regimen with lisaftoclax yielded impressive clinical data.

For lisaftoclax, updated registrational Phase II data in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) were presented. Stratified analysis based on baseline characteristics and prognostic correlations provided important references for refining treatment strategies for different patient populations and optimizing individualized dosing regimens.

Real-world data for lisaftoclax in myeloid neoplasms also provided strong corroboration of its clinical value.